Prostox™ is a genomic test that analyzes a patient’s inherited genetic markers (microRNA-related variants) to predict their risk of developing long-term urinary side effects after prostate radiation therapy. By identifying high-risk patients before treatment begins, Prostox™ may help doctors personalize radiation strategies and improve treatment planning.

What Is Prostox™?

When someone is diagnosed with prostate cancer, one of the biggest decisions they face is choosing the right treatment. Radiation therapy is highly effective for many men, but one concern remains: not everyone experiences side effects in the same way.

Some patients complete radiation with minimal problems, while others develop persistent urinary symptoms such as urgency, frequency, leakage, pain during urination, or blood in the urine months after treatment.

Until recently, doctors had very few tools to predict who might experience these complications.

Prostox™ aims to change that.

Developed using years of radiogenomics research, Prostox™ is the first genomic test specifically designed to predict the likelihood of developing long-term urinary toxicity following prostate radiation therapy, particularly stereotactic body radiotherapy (SBRT). Rather than examining the tumor itself, the test analyzes a person’s inherited genetic profile to estimate how normal tissues may respond to radiation. 

Why Is Predicting Radiation Side Effects So Important?

Radiation therapy has become one of the standard treatments for localized prostate cancer.

Modern techniques such as:

• Image-guided radiation therapy (IGRT)
• Intensity-modulated radiation therapy (IMRT)
• Stereotactic body radiation therapy (SBRT)

have significantly reduced complications compared with older radiation methods.

However, even with these technological improvements, some men still develop late urinary toxicity.

These side effects may include:

• Increased urinary frequency
• Urinary urgency
• Burning during urination
• Blood in urine (hematuria)
• Urinary leakage
• Difficulty emptying the bladder
• Chronic urinary discomfort

For many patients, these symptoms can persist for years and negatively affect quality of life. Researchers believe that part of this variation is explained not only by radiation dose or treatment technique but also by genetic differences between individuals.

How Does Prostox™ Work?

Unlike PSA tests or genomic tests that evaluate cancer aggressiveness, Prostox™ focuses on the patient’s inherited DNA.

The test examines specific microRNA-related single nucleotide polymorphisms (mirSNPs)—small inherited genetic variations that influence how healthy tissues repair themselves after radiation exposure.

MicroRNAs regulate hundreds of genes involved in:

• DNA repair
• Cell signaling
• Inflammation
• Tissue healing
• Radiation response

Certain inherited variants appear to make some patients much more sensitive to radiation than others.

Using machine-learning models trained on clinical datasets, Prostox™ combines these genetic markers into a predictive score that estimates the likelihood of developing late urinary toxicity after radiation therapy. 

What Makes Prostox™ Different from Other Prostate Cancer Tests?

Many genomic tests already exist for prostate cancer.

Examples include tests that help determine:

• Whether active surveillance is appropriate
• The aggressiveness of a tumor
• Risk of recurrence
• Whether additional treatment is needed after surgery

Prostox™ serves a completely different purpose.

Instead of predicting how aggressive the cancer is, it predicts how your body is likely to tolerate radiation therapy.

That distinction makes Prostox™ one of the first clinically validated toxicity prediction tests in prostate cancer care.

This represents an important shift toward truly personalized medicine, where treatment decisions consider not only the cancer but also the patient’s individual biology. 

Who Should Consider Prostox™?

Although the test is still being incorporated into clinical practice, current evidence suggests it may be particularly useful for men who are:

• Considering stereotactic body radiotherapy (SBRT)
• Choosing between surgery and radiation
• Concerned about long-term urinary quality of life
• Eligible for multiple treatment options
• Interested in personalized treatment planning

For these patients, understanding their genetic susceptibility before treatment could support more informed discussions with their radiation oncologist.

Importantly, Prostox™ does not determine whether radiation will cure the cancer. Instead, it estimates the patient’s risk of experiencing significant urinary side effects from radiation.

What Does the Clinical Research Say About Prostox™?

Interest in Prostox™ has grown following several validation studies led by researchers at UCLA and collaborating institutions.

A study published in Clinical Cancer Research validated the test in patients undergoing prostate SBRT and found that Prostox™ successfully identified men at increased risk of developing late-grade 2 or higher genitourinary toxicity.

According to UCLA researchers, patients identified as high risk were approximately 10 to 12 times more likely to develop long-term urinary side effects than those classified as low risk. These findings suggest that inherited genetic differences play a major role in determining how patients respond to radiation treatment. 

Researchers also evaluated the genetic signature in additional patient populations, including men receiving radiation after prostatectomy, where the model continued to demonstrate predictive value. 

Why Could Prostox™ Change the Future of Personalized Radiation Therapy?

Historically, radiation treatment decisions have relied on clinical factors such as:

• PSA level
• Gleason score
• MRI findings
• Tumor stage
• Age
• Overall health

These remain essential, but they do not explain why two patients receiving nearly identical treatment can have completely different long-term experiences.

Prostox™ adds another layer of information: genetic susceptibility.

If validated further across larger populations, this type of genomic testing could allow physicians to:

• Choose alternative radiation schedules for high-risk patients
• Consider different treatment approaches when appropriate
• Counsel patients more accurately about expected side effects
• Improve shared decision-making before treatment begins

Rather than applying a “one-size-fits-all” approach, radiation therapy could become increasingly tailored to each patient’s biology. 

What Are the Benefits of Prostox™ for Patients and Clinicians?

One of the biggest advantages of Prostox™ is that it moves prostate cancer care closer to precision medicine. Rather than assuming every patient has the same risk of radiation-related side effects, the test provides individualized information that can help guide treatment discussions.

Potential benefits include:

• More personalized treatment decisions
• Better informed consent before radiation begins
• Improved patient counseling regarding long-term urinary risks
• Identification of patients who may benefit from alternative radiation strategies
• Greater confidence when choosing between SBRT and other treatment approaches, when clinically appropriate

Importantly, Prostox™ is not intended to replace the expertise of a radiation oncologist. Instead, it adds another piece of information to consider alongside PSA levels, MRI findings, biopsy results, Gleason Grade Group, age, urinary function, and overall health. Clinical studies suggest that PROSTOX provides predictive information beyond traditional clinical and dosimetric variables.

What Are the Limitations of Prostox™?

Although Prostox™ is an exciting development, it is important to understand its current limitations.

1. It predicts toxicity, not treatment success

A low-risk Prostox™ result does not mean radiation will be more effective at eliminating prostate cancer.

Likewise, a high-risk result does not mean radiation should automatically be avoided.

The test predicts the likelihood of urinary side effects, not cancer control.

2. Clinical judgment remains essential

Treatment decisions should be based on multiple factors, including:

• Cancer stage
• PSA level
• MRI findings
• Gleason Grade Group
• Patient age
• Life expectancy
• Baseline urinary symptoms
• Personal preferences

Prostox™ should be viewed as an additional decision-support tool rather than a standalone test.

3. Ongoing validation is still underway

Although the validation studies are encouraging, researchers continue to evaluate Prostox™ in larger and more diverse patient populations.

Future studies will determine:

• How well it performs across different radiation techniques
• Whether it predicts bowel toxicity or sexual side effects
• Its usefulness in broader clinical practice
• How it influences long-term treatment decisions and patient outcomes

These are common steps in the adoption of any new genomic biomarker.

When Might a Doctor Recommend Prostox™?

Your doctor may discuss Prostox™ if you:

• Are considering radiation therapy for localized prostate cancer.
• Are deciding between SBRT and a more conventional radiation schedule.
• Have multiple treatment options and want additional information about potential long-term urinary side effects.
• Value a personalized approach to treatment planning.

Because Prostox™ is relatively new, not every cancer center currently offers it. If you’re interested, ask your radiation oncologist whether genomic toxicity testing is available and appropriate for your situation.

Conclusion

Prostox™ represents an important step toward personalized prostate cancer care. Instead of treating every patient as though they have the same likelihood of developing radiation-related side effects, this genomic test helps identify those who may be more susceptible to long-term urinary toxicity based on their inherited genetic profile.

While Prostox™ is not a replacement for clinical expertise, it provides valuable information that can enhance conversations between patients and radiation oncologists. As additional validation studies are completed and more treatment centers adopt genomic toxicity testing, Prostox™ may become an increasingly useful component of individualized radiation therapy planning.

For men considering radiation therapy, especially SBRT, discussing Prostox™ with a qualified radiation oncologist may help ensure that treatment decisions are informed by both the characteristics of the cancer and the biology of the individual patient.

Key Takeaways

• Prostox™ is a genomic test designed to predict the risk of long-term urinary side effects after prostate radiation therapy.
• It analyzes inherited microRNA-related genetic variants (mirSNPs) rather than the cancer itself.
• The test supports personalized treatment planning and shared decision-making.
• Current evidence suggests Prostox™ can identify patients at increased risk of late urinary toxicity following SBRT.
• It is not a diagnostic test for prostate cancer and does not predict whether radiation will cure the disease.
• Although promising, Prostox™ should be interpreted alongside clinical judgment and other established diagnostic tools.

FAQs